579 related articles for article (PubMed ID: 23673355)
1. Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice.
Akazawa D; Moriyama M; Yokokawa H; Omi N; Watanabe N; Date T; Morikawa K; Aizaki H; Ishii K; Kato T; Mochizuki H; Nakamura N; Wakita T
Gastroenterology; 2013 Aug; 145(2):447-55.e1-4. PubMed ID: 23673355
[TBL] [Abstract][Full Text] [Related]
2. Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine.
Beaumont E; Patient R; Hourioux C; Dimier-Poisson I; Roingeard P
Hepatology; 2013 Apr; 57(4):1303-13. PubMed ID: 23150224
[TBL] [Abstract][Full Text] [Related]
3. Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice.
Cao J; Chen Z; Ren Y; Luo Y; Cao M; Lu W; Zhao P; Qi Z
Vaccine; 2011 May; 29(20):3714-23. PubMed ID: 21396407
[TBL] [Abstract][Full Text] [Related]
4. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
Vietheer PT; Boo I; Drummer HE; Netter HJ
Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
[TBL] [Abstract][Full Text] [Related]
5. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
[TBL] [Abstract][Full Text] [Related]
6. [Study of neutralization antibodie induced by DNA vaccine of HCV envelope protein 2 in mice].
Shao S; Zhou H; Tong Y; Ren Y; Chen Z
Wei Sheng Yan Jiu; 2011 May; 40(3):295-8. PubMed ID: 21695897
[TBL] [Abstract][Full Text] [Related]
7. N-glycosylation-mutated HCV envelope glycoprotein complex enhances antigen-presenting activity and cellular and neutralizing antibody responses.
Ren Y; Min YQ; Liu M; Chi L; Zhao P; Zhang XL
Biochim Biophys Acta; 2016 Aug; 1860(8):1764-75. PubMed ID: 26278021
[TBL] [Abstract][Full Text] [Related]
8. Neutralization effects of antibody elicited by chimeric HBV S antigen viral-like particles presenting HCV neutralization epitopes.
Wei S; Lei Y; Yang J; Wang X; Shu F; Wei X; Lin F; Li B; Cui Y; Zhang H; Wei S
Vaccine; 2018 Apr; 36(17):2273-2281. PubMed ID: 29576303
[TBL] [Abstract][Full Text] [Related]
9. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
[TBL] [Abstract][Full Text] [Related]
10. Antibodies Targeting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection.
Deng K; Liu R; Rao H; Jiang D; Wang J; Xie X; Wei L
PLoS One; 2015; 10(9):e0138756. PubMed ID: 26406225
[TBL] [Abstract][Full Text] [Related]
11. Thromboxane A2 synthase inhibitors prevent production of infectious hepatitis C virus in mice with humanized livers.
Abe Y; Aly HH; Hiraga N; Imamura M; Wakita T; Shimotohno K; Chayama K; Hijikata M
Gastroenterology; 2013 Sep; 145(3):658-67.e11. PubMed ID: 23684750
[TBL] [Abstract][Full Text] [Related]
12. New neutralizing antibody epitopes in hepatitis C virus envelope glycoproteins are revealed by dissecting peptide recognition profiles.
Kachko A; Kochneva G; Sivolobova G; Grazhdantseva A; Lupan T; Zubkova I; Wells F; Merchlinsky M; Williams O; Watanabe H; Ivanova A; Shvalov A; Loktev V; Netesov S; Major ME
Vaccine; 2011 Dec; 30(1):69-77. PubMed ID: 22041300
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing antibodies and broad, functional T cell immune response following immunization with hepatitis C virus proteins-based vaccine formulation.
Martinez-Donato G; Amador-Cañizares Y; Alvarez-Lajonchere L; Guerra I; Pérez A; Dubuisson J; Wychowsk C; Musacchio A; Aguilar D; Dueñas-Carrera S
Vaccine; 2014 Mar; 32(15):1720-6. PubMed ID: 24486345
[TBL] [Abstract][Full Text] [Related]
14. Incorporation of primary patient-derived glycoproteins into authentic infectious hepatitis C virus particles.
Doerrbecker J; Friesland M; Riebesehl N; Ginkel C; Behrendt P; Brown RJ; Ciesek S; Wedemeyer H; Sarrazin C; Kaderali L; Pietschmann T; Steinmann E
Hepatology; 2014 Aug; 60(2):508-20. PubMed ID: 24771613
[TBL] [Abstract][Full Text] [Related]
15. A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections.
Kosaka K; Hiraga N; Imamura M; Yoshimi S; Murakami E; Nakahara T; Honda Y; Ono A; Kawaoka T; Tsuge M; Abe H; Hayes CN; Miki D; Aikata H; Ochi H; Ishida Y; Tateno C; Yoshizato K; Sasaki T; Chayama K
Biochem Biophys Res Commun; 2013 Nov; 441(1):230-5. PubMed ID: 24140055
[TBL] [Abstract][Full Text] [Related]
16. Progress toward development of a hepatitis C vaccine with broad shoulders.
Ray R
Sci Transl Med; 2011 Aug; 3(94):94ps33. PubMed ID: 21813753
[TBL] [Abstract][Full Text] [Related]
17. Genetic immunization of wild-type and hepatitis C virus transgenic mice reveals a hierarchy of cellular immune response and tolerance induction against hepatitis C virus structural proteins.
Satoi J; Murata K; Lechmann M; Manickan E; Zhang Z; Wedemeyer H; Rehermann B; Liang TJ
J Virol; 2001 Dec; 75(24):12121-7. PubMed ID: 11711603
[TBL] [Abstract][Full Text] [Related]
18. Development of a heterologous, multigenotype vaccine against hepatitis C virus infection.
Encke J; Radunz W; Eisenbach C; Geib J; Gehrke S; Pfaff E; Stremmel W
Eur J Clin Invest; 2007 May; 37(5):396-406. PubMed ID: 17461986
[TBL] [Abstract][Full Text] [Related]
19. Expression, purification and immunogenic characterization of hepatitis C virus recombinant E1E2 protein expressed by Pichia pastoris yeast.
Cai W; Su L; Liao Q; Ye L; Wu Y; Wu Z; She Y
Antiviral Res; 2010 Oct; 88(1):80-5. PubMed ID: 20691736
[TBL] [Abstract][Full Text] [Related]
20. Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice.
Pihl AF; Feng S; Offersgaard A; Alzua GP; Augestad EH; Mathiesen CK; Jensen TB; Krarup H; Law M; Prentoe J; Christensen JP; Bukh J; Gottwein JM
J Hepatol; 2022 May; 76(5):1051-1061. PubMed ID: 34990750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
